SRRK

Scholar Rock Holding Corp

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1727196Held by 5 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$0.0M

Net Income FY2025

$(378.0M)

EPS (Basic, as reported)

$-3.29

Net Margin FY2025

—

ROE FY2025

-154.0%

Total Equity

$245.0M

Shares Out

122M

Business description

Scholar Rock Holding Corp — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2017–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 0

Fiscal yearFY2017FY2018FY2019FY2020FY2021⚑FY2022FY2023FY2024FY2025

Revenue—020151933——0

Research & development(20)(36)(54)(74)(108)(124)(122)(185)(208)

General & administrative(5)(14)(21)(28)(40)(43)(49)(68)(176)

Total operating expenses(25)(51)(75)(102)(149)(168)(171)(252)(385)

Operating income(25)(51)(55)(87)(130)(134)(171)(252)(385)

Interest expense——00(2)(5)(6)(7)(7)

Other income (expense), net0140(2)0667

Net income(25)(49)(51)(86)(132)(135)(166)(246)(378)

EPS — basic———($2.81)($3.59)($2.26)($1.99)($2.47)($3.29)

EPS — diluted———($2.81)($3.59)($2.26)($1.99)($2.47)($3.29)

Shares outstanding — basic (M)———31376083100115

Shares outstanding — diluted (M)———31376083100115

⚑ Weighted-average shares changed ×1.62 between FY2021 and FY2022 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.